Uncategorized

Short answer: a weak Pre-Submission (Pre-Sub) does not just waste a meeting with the FDA. It creates a regulatory record that can follow your device through the rest of development. Many founders treat a Pre-Sub as a casual conversation with the U.S. Food and Drug Administration. In reality, it is a formal interaction within the FDA’s Q-Submission program. The discussion becomes part of the agency’s internal regulatory history for your device.

Short answer: FDA failure is not just a regulatory setback. It is a valuation event. When a medical device company receives a major deficiency letter, Refuse-to-Accept decision, or pathway escalation from the U.S. Food and Drug Administration, investors do not see a technical issue. They see risk materializing. And risk directly affects exits.

Short answer: most FDA submission failures follow predictable patterns. They are rarely random. They are rarely mysterious. And they are almost always preventable. Startups often assume failure happens because the science was weak. In reality, failure usually happens because the regulatory strategy was fragmented, optimistic, or reactive

Short answer: investors do not just look at your FDA pathway. They look at how realistic your pathway assumptions are. If your regulatory strategy sounds optimistic, […]